| Tue, Nov 24, 2009 |
| • |
Cel-Sci's History of Disappearing Drugs: BioBuzz
at TheStreet.com (Tue 9:20am)
|
| • |
BioCryst Bull Blames Conspiracy for Stock's Fall: BioBuzz
at TheStreet.com (Tue 6:45am)
|
| Fri, Nov 20, 2009 |
| • |
Dendreon says FDA will disclose Provengeâs fate by May 1
at bizjournals.com (Fri, Nov 20)
|
| • |
May Day For Dendreon
at CNBC (Fri, Nov 20)
|
| • |
Dendreon's Provenge gets FDA review date
AP (Fri, Nov 20)
|
| • |
Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript (Fri, Nov 20)
|
| • |
UPDATE - FDA says Dendreon's drug application is complete
at Reuters (Fri, Nov 20)
|
| • |
Dendreon Receives FDA Acknowledgement of Complete Response
PRNewswire (Fri, Nov 20)
|
| • |
Biotech Stock Mailbag: FDA Playbook
at TheStreet.com (Fri, Nov 20)
|
| Tue, Nov 17, 2009 |
| • |
This Is Why You're Not Making Money in the Market
at Motley Fool (Tue, Nov 17)
|
| • |
[$$] Mixed Start
at RealMoney by TheStreet.com (Tue, Nov 17)
|
| Fri, Nov 13, 2009 |
| • |
DENDREON CORP Financials
EDGAR Online Financials (Fri, Nov 13)
|
| Thu, Nov 12, 2009 |
| • |
DENDREON CORP Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Thu, Nov 12)
|
| • |
Spectrum Posts Encouraging Zevalin Sales: BioBuzz
at TheStreet.com (Thu, Nov 12)
|
| Wed, Nov 11, 2009 |
| • |
Earnings roundup: Applied Materials, Macy's
AP (Wed, Nov 11)
|
| • |
Dendreon loses $45.6M in Q3
at bizjournals.com (Wed, Nov 11)
|
| • |
Dendreon 3Q loss widens on expenses, charge
AP (Wed, Nov 11)
|
| • |
Dendreon Corporation Third Quarter 2009 Financial Results Call scheduled for 4:30 pm ET today
Shareholder.com (Wed, Nov 11)
|
| • |
Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization -- Conference Call to be Hosted Today
PRNewswire (Wed, Nov 11)
|
| Mon, Nov 9, 2009 |
| • |
UPDATE - Dendreon Q3 loss wider than expected on higher expenses
at Reuters (Mon, Nov 9)
|
| Older Headlines |
|
|
|
|
Help
0.34 (1.23%) 
Headlines
